A Director at Aravive (NASDAQ: ARAV) is Buying Shares

Today, a Director at Aravive (ARAVResearch Report), Srinivas Akkaraju, bought shares of ARAV for $1000K.

This recent transaction increases Srinivas Akkaraju’s holding in the company by 28.1% to a total of $5.85 million.

See today’s analyst top recommended stocks >>

The company has a one-year high of $15.62 and a one-year low of $3.07. Currently, Aravive has an average volume of 114.30K.

Starting in April 2019, ARAV received 6 Buy ratings in a row.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aravive, Inc. is a clinical-stage biotechnology company, which engages in developing new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments, and immune suppression. The company was founded on December 10, 2008 and is headquartered in Houston, TX.